植物甾醇酯和葛根素复合微胶囊的制备工艺优化
|
摘要
以植物甾醇酯和葛根素为芯材,阿拉伯胶和β-环状糊精为壁材,采用喷雾干燥法制备植物甾醇酯葛根素复合微胶囊。考察了乳化剂配比、乳化剂用量、固形物含量、芯壁比、壁材比对乳化液稳定性的影响,以及进风温度、出风温度、均质压力对微胶囊化效率的影响,通过单因素试验和正交试验,确定复合微胶囊的最佳工艺参数。结果显示,复合微胶囊的最佳工艺条件为:乳化剂(蔗糖酯-单甘酯)配比6∶4(g/g)、乳化剂用量0.7%(质量分数)、固形物含量20%(质量分数)、芯壁比0.25∶1(g/g)、壁材(阿拉伯胶和β-环状糊精)比5∶5(g/g)、进风温度180℃、出风温度75℃、均质压力25 MPa。在此工艺条件下复合微胶囊中植物甾醇酯的包埋率为89.04%,葛根素包埋率为80.15%,产品为乳白色、细小均匀的粉末,气味纯正,密度0.568 g/m L,溶解率95.11%,水分含量3.57%,贮藏稳定性提高。
Using gum arabic and β-cyclodextrin as wall materials, blend microcapsules of phytosterol esters and puerarin were prepared by a spray drying method. The influences of emulsifier composition, emulsifier dosage, solids content, core material-to-wall material ratio, and gum Arabic-to-β-cyclodextrin ratio on emulsion stability were investigated as well as the influences of inlet temperature, outlet temperature and homogenization pressure on microencapsulation efficiency. The optimum processing parameters for the preparation of composite microcapsules were determined by combined use of single factor and orthogonal array experiments as follows: emulsifier dosage(sucrose ester : monoglyceride = 6:4, g/g), 0.7%; solid content, 20%; core material/wall material ratio, 0.25:1; wall material composition, acacia senegal:β-cyclodextrin = 5:5; inlet temperature, 180 ℃; outlet temperature, 75 ℃; and homogenization pressure, 25 MPa. Under the optimum conditions, the microencapsulation efficiency of phytostetol esters and puerarin were 89.04% and 80.15%, respectively. The composite microcapsule was a milky white, uniform fine powder that smells pure. It had a moisture of 3.57%, density of 0.568 g/m L and solubility of 95.11%, and exhibited high storage stability.
Using gum arabic and β-cyclodextrin as wall materials, blend microcapsules of phytosterol esters and puerarin were prepared by a spray drying method. The influences of emulsifier composition, emulsifier dosage, solids content, core material-to-wall material ratio, and gum Arabic-to-β-cyclodextrin ratio on emulsion stability were investigated as well as the influences of inlet temperature, outlet temperature and homogenization pressure on microencapsulation efficiency. The optimum processing parameters for the preparation of composite microcapsules were determined by combined use of single factor and orthogonal array experiments as follows: emulsifier dosage(sucrose ester : monoglyceride = 6:4, g/g), 0.7%; solid content, 20%; core material/wall material ratio, 0.25:1; wall material composition, acacia senegal:β-cyclodextrin = 5:5; inlet temperature, 180 ℃; outlet temperature, 75 ℃; and homogenization pressure, 25 MPa. Under the optimum conditions, the microencapsulation efficiency of phytostetol esters and puerarin were 89.04% and 80.15%, respectively. The composite microcapsule was a milky white, uniform fine powder that smells pure. It had a moisture of 3.57%, density of 0.568 g/m L and solubility of 95.11%, and exhibited high storage stability.
引文
[1]CHEN Wangchuang,HAYAKAWA S,YAMAMTO T,et al.Mediation ofβ-endorphin by the isoflavone puerarin to lower plasma glucose in streptozotocin-induced diabetic rats[J].Planta Medica,2004,70(2):113-116.DOI:10.1055/s-2004-835851.
[2]张利夫,陈少伟.葛根素对高脂血症患者ET、NO及血脂的影响[J].医学临床研究,2008,25(8):1417-1419.
[3]VILLENEVE P,TURON F,CARO Y,et al.Lipase-catalyzed synthesis of canola phytosterols oleate esters as cheolesterol lowering agents[J].Enzyme and Microbial Technology,2005,37:150-155.DOI:10.1016/j.enzmictec.2005.02.002.
[4]YANKAH V V,JONES P J H.Phytosterols and health implicationscommercial products and their regulation[J].Inform-International News on Fats Oils and Related Materials,2001,12(10):1011-1017.
[5]BLAIR S N,CAPUZZI D M,GOTTLIEB S O,et al.Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy[J].American Journal of Cardiology,2000,86(1):46-52.
[6]GABAY O,SANCHEZ C,SALVAT C,et al.Stigmasterol:a phytosterol with potential anti-osteoarthritic properties[J].Osteoarthritis Cartilage,2010,18(1):106-116.
[7]STEFANI E D,BOFFETTA P,RONCO A L,et al.Plant sterols and risk of stomach cancer:a case-control study in Uruguay[J].Nutr Cancer,2000,37(2):140-144.DOI:10.1207/S15327914NC3724.
[8]刘虹蕾,缪铭,江波等.植物甾醇酯的研究与分析[J].食品工业科技,2012,33(4):434-437.
[9]程远渡,易有金,易传祝,等.植物甾醇酯和葛根素联合使用对高脂血症小鼠降血脂作用研究[J].中国油脂,2015,40(4):64-68.
[10]崔炳群,王三永,李晓光,等.植物甾醇酯微胶囊化研究[J].食品工业科技,2002,23(7):25-29.
[11]刘福斌,张根生,刘广,等.微胶囊化玉米胚芽油粉的研制[J].现代食品科技,2011,27(2):173-177.DOI:10.3969/j.issn.1673-9078.2011.02.014.
[12]徐文秀,吴彩娥,李强,等.丁香油喷雾干燥微胶囊技术研究[J].食品科学,2006,27(1):278-281.DOI:10.3321/j.issn:1002-6630.2006.01.066.
[13]刘全亮,马传国,季敏,等.棕榈油微胶囊化制备工艺研究[J].粮食与油脂,2014,27(1):32-35.
[14]赵巍,王军,段长青,等.喷雾干燥法制备微胶囊化山葡萄籽油粉末油脂[J].中国粮油学报,2009,24(12):77-83.
[15]郭立华.玉米醇溶蛋白微胶囊的制备及性质研究[D].天津:天津科技大学,2012.
[16]夏辉,刘欣荣.甾醇酯微胶囊制备工艺研究[J].粮油食品科技,2012,20(1):30-33.DOI:10.3969/j.issn.1007-7561.2012.01.009.
[17]王丽娟,李志芬,闫新丽,等.芝麻油微胶囊化复合壁材的选择及工艺条件的研究[J].油脂工程,2007(3):56-58.
[18]陈琳,李荣,姜子涛,等.微胶囊化方法对紫苏油包埋性能的比较研究[J].食品工业科技,2013,34(20):176-180.
[19]冯岩.复合凝聚法制备维生素E微胶囊的研究[D].无锡:江南大学,2008.
[20]康吟,陶宁萍,王锡昌.喷雾干燥法制取宝石鱼油微胶囊技术的研究[J].现代食品科技,2007,23(7):59-62.
[21]吴姣,郑为完,周德红,等.粉末油脂过氧化值测定方法的研究[J].中国油脂,2006,31(7):54-55.DOI:10.3321/j.issn:1003:7969.2006.07.016.
[22]魏巍,李敏,李纯,等.1,3-二油酸-2-棕榈酸结构油脂微胶囊的研制[J].食品工业科技,2013,34(20):294-301.
[23]冯卫华,刘邻渭,许克勇.猕猴桃籽油微胶囊化技术研究[J].农业工程学报,2004,20(1):234-237.DOI:10.3321/j.issn:1002-6819.2004.01.056.
[24]LIU Xiangdong,ATARASHI T,FURUTA T,et al.Microencapsulation of emulsified hydrophobic flavors by spray dying[J].Drying Technology,2001,19(7):1361-1374.DOI:10.1081/DRT-100105293.
[25]张旭.五味子木脂素微胶囊的研制及其抗疲劳功效研究[D].长春:吉林农业大学,2008.
[2]张利夫,陈少伟.葛根素对高脂血症患者ET、NO及血脂的影响[J].医学临床研究,2008,25(8):1417-1419.
[3]VILLENEVE P,TURON F,CARO Y,et al.Lipase-catalyzed synthesis of canola phytosterols oleate esters as cheolesterol lowering agents[J].Enzyme and Microbial Technology,2005,37:150-155.DOI:10.1016/j.enzmictec.2005.02.002.
[4]YANKAH V V,JONES P J H.Phytosterols and health implicationscommercial products and their regulation[J].Inform-International News on Fats Oils and Related Materials,2001,12(10):1011-1017.
[5]BLAIR S N,CAPUZZI D M,GOTTLIEB S O,et al.Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy[J].American Journal of Cardiology,2000,86(1):46-52.
[6]GABAY O,SANCHEZ C,SALVAT C,et al.Stigmasterol:a phytosterol with potential anti-osteoarthritic properties[J].Osteoarthritis Cartilage,2010,18(1):106-116.
[7]STEFANI E D,BOFFETTA P,RONCO A L,et al.Plant sterols and risk of stomach cancer:a case-control study in Uruguay[J].Nutr Cancer,2000,37(2):140-144.DOI:10.1207/S15327914NC3724.
[8]刘虹蕾,缪铭,江波等.植物甾醇酯的研究与分析[J].食品工业科技,2012,33(4):434-437.
[9]程远渡,易有金,易传祝,等.植物甾醇酯和葛根素联合使用对高脂血症小鼠降血脂作用研究[J].中国油脂,2015,40(4):64-68.
[10]崔炳群,王三永,李晓光,等.植物甾醇酯微胶囊化研究[J].食品工业科技,2002,23(7):25-29.
[11]刘福斌,张根生,刘广,等.微胶囊化玉米胚芽油粉的研制[J].现代食品科技,2011,27(2):173-177.DOI:10.3969/j.issn.1673-9078.2011.02.014.
[12]徐文秀,吴彩娥,李强,等.丁香油喷雾干燥微胶囊技术研究[J].食品科学,2006,27(1):278-281.DOI:10.3321/j.issn:1002-6630.2006.01.066.
[13]刘全亮,马传国,季敏,等.棕榈油微胶囊化制备工艺研究[J].粮食与油脂,2014,27(1):32-35.
[14]赵巍,王军,段长青,等.喷雾干燥法制备微胶囊化山葡萄籽油粉末油脂[J].中国粮油学报,2009,24(12):77-83.
[15]郭立华.玉米醇溶蛋白微胶囊的制备及性质研究[D].天津:天津科技大学,2012.
[16]夏辉,刘欣荣.甾醇酯微胶囊制备工艺研究[J].粮油食品科技,2012,20(1):30-33.DOI:10.3969/j.issn.1007-7561.2012.01.009.
[17]王丽娟,李志芬,闫新丽,等.芝麻油微胶囊化复合壁材的选择及工艺条件的研究[J].油脂工程,2007(3):56-58.
[18]陈琳,李荣,姜子涛,等.微胶囊化方法对紫苏油包埋性能的比较研究[J].食品工业科技,2013,34(20):176-180.
[19]冯岩.复合凝聚法制备维生素E微胶囊的研究[D].无锡:江南大学,2008.
[20]康吟,陶宁萍,王锡昌.喷雾干燥法制取宝石鱼油微胶囊技术的研究[J].现代食品科技,2007,23(7):59-62.
[21]吴姣,郑为完,周德红,等.粉末油脂过氧化值测定方法的研究[J].中国油脂,2006,31(7):54-55.DOI:10.3321/j.issn:1003:7969.2006.07.016.
[22]魏巍,李敏,李纯,等.1,3-二油酸-2-棕榈酸结构油脂微胶囊的研制[J].食品工业科技,2013,34(20):294-301.
[23]冯卫华,刘邻渭,许克勇.猕猴桃籽油微胶囊化技术研究[J].农业工程学报,2004,20(1):234-237.DOI:10.3321/j.issn:1002-6819.2004.01.056.
[24]LIU Xiangdong,ATARASHI T,FURUTA T,et al.Microencapsulation of emulsified hydrophobic flavors by spray dying[J].Drying Technology,2001,19(7):1361-1374.DOI:10.1081/DRT-100105293.
[25]张旭.五味子木脂素微胶囊的研制及其抗疲劳功效研究[D].长春:吉林农业大学,2008.